Navigation Links
Kinex Pharmaceuticals To Present at ASCO 2009 Annual Meeting
Date:5/27/2009

BUFFALO, N.Y., May 27 /PRNewswire/ -- Kinex Pharmaceuticals will present results from a Phase 1 clinical study with KX2-391, at the ASCO 2009 Annual Meeting in Orlando, on May 29, 2009. The study was carried out at MD Anderson, Roswell Park Cancer Institute (RPCI) and Fox Chase Cancer Center. Dr. Alex Adjei, the Principal Investigator from RPCI will deliver the presentation entitled "Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies."

The presentation will provide data from this multi-center Phase 1 trial that utilized the standard 3+3 design to determine the Maximum Tolerated Dose (MTD), safety, and pharmacokinetics (PK) of KX2-391 in patients with refractory solid tumors. Patients who responded to treatment will be highlighted.

This presentation was designated as Best of ASCO(R) which features high-impact abstracts from the 2009 ASCO Annual Meeting that represent the most relevant, cutting-edge science in oncology today. This information has been selected to be presented at meetings in the US and internationally because it highlights the latest scientific findings in primary disease sites and practice-changing advances in cancer prevention and treatment.

Kinex Pharmaceuticals is a drug discovery and development company that is focused on next generation drugs to treat cancer and immuno-inflammatory diseases. The Company has utilized its platform technologies to identify highly selective inhibitors of therapeutically relevant targets that are involved in signal transduction and cell cycle control.

CONTACT: Lyn Dyster, Vice President, Research Operations of Kinex Pharmaceuticals, +1-716-881-8984


'/>"/>
SOURCE Kinex Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very pleased ... as its new Chief Executive Officer.  Mark was promoted ... he has overseen the company,s four facilities in ... Rica.  Mr. King joined Tegra Medical in 2012 with 20+ ...
(Date:1/15/2014)... Ill. , Jan. 15, 2014 The Cadence ... Medical Fitness Center by the Medical Fitness Association, a ... to achieve their full potential. The Cadence Fitness & ... the western suburbs and second in the Chicagoland area. ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... ATLANTA, Nov. 28, 2011   CardioMEMS, Inc ., an ... commercializing a proprietary wireless sensing and communication technology for ... CEO, Jay Yadav, M.D. , has been recognized ... Endeavor Awards in the Technology Entrepreneur category. The awards ...
... (NYSE Amex: PIP ), a biodefense company ... today that Eric I. Richman, President and Chief Executive ... Healthcare Conference being held November 29-30, 2011.  ... in one-on-one meetings at the conference.Event : , ...
Cached Medicine Technology:TechAmerica and the Technology Association of Georgia Name Dr. Jay Yadav, CardioMEMS Founder & CEO as a Spirit of Endeavor Award Finalist 2TechAmerica and the Technology Association of Georgia Name Dr. Jay Yadav, CardioMEMS Founder & CEO as a Spirit of Endeavor Award Finalist 3PharmAthene to Present at the Piper Jaffray 23rd Annual Healthcare Conference on November 30, 2011 2
(Date:4/17/2014)... TORONTO, April 17, 2014 Giving patients adrenaline after they ... not increase their prospects of surviving long-term, according to ... vast number of patients who have a cardiac arrest ... treating cardiac arrest for decades," said Dr. Steve Lin, ... Michael,s. "Yet, despite advances in medical treatment, long-term survival ...
(Date:4/16/2014)... 15, 2014 The Translational Genomics Research Institute (TGen) ... Founders Dinner for their support of TGen,s research into ... March 28 in Scottsdale. , Catherine Ivy, Founder and ... TGen,s John S. McCain Leadership Award, named for U.S. ...
(Date:4/15/2014)... pre-diabetes in the United States have nearly doubled since 1988, ... Public Health, with obesity apparently to blame for the surge. ... has not hit all groups equally, with alarming increases in ... new research reported in the April 15, 2014 issue of ...
(Date:4/14/2014)... over the past decade, but targeting drugs to cancer ... major challenge. , Nanotechnology has unlocked new pathways ... or capsules, that can transport cargoes of small-molecule therapeutics ... These carriers are tiny, and it matters just how ...
(Date:4/14/2014)... IL A new study shows that moderate to severe obstructive ... cancer and death. , Results of the 20-year follow-up study show ... times more likely to die (hazard ratio = 4.2), nearly four ... times more likely to die from cancer (HR = 3.4), and ...
Breaking Medicine News(10 mins):Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Nano shake-up 2Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2
... Awareness of Lupus and ... Funds for Lupus Foundation of America, WASHINGTON, Sept. 13 ... Houston, Texas, two recent,college graduates, will end their 15 week ... 4,000 miles from Bellingham,Washington to Charleston, South Carolina. The ...
... Novelli as MDMA,s Director of Federal Affairs, ... (MDMA) is pleased to announce the appointment of,Thomas ... Affairs., (Photo: http://www.newscom.com/cgi-bin/prnh/20041004/MDMALOGO ), ... Senate Committee on Finance,for Senator Charles Grassley from ...
... explores industry trends and the utilization of ... 13 Visiprise, Inc., a leader in,manufacturing execution ... the company will host a series of podcast ... Titled "Operational,Efficiency in Medical Device Manufacturing," these free, ...
... SAN DIEGO, Sept. 13 NuVasive, Inc. (Nasdaq:,NUVA), ... for,minimally disruptive surgical treatments for the spine, announced ... and Kevin,O,Boyle, Executive Vice President and Chief Financial ... 5th Annual Growth,Conference at the St. Regis Hotel, ...
... China,Shenghuo Pharmaceutical Holdings, Inc. ("China Shenghuo," "the ... in the research, development, manufacture,and marketing of ... People,s Republic of China ("PRC"), today announced ... Chinese herbal skin care,products ("12Ways") on Sunday, ...
... Education Council raises awareness about prostate cancer ... and related health concerns, ... he,has prostate cancer -- the second-leading cause of cancer death in ... making prostate,cancer among men more prevalent than breast cancer among women. ...
Cached Medicine News:Health News:Bike Ride Across the U.S. to End Saturday at Folly Beach 2Health News:MDMA Names New Director of Federal Affairs 2Health News:Visiprise Launches Podcast Series with AMR to Support Medical Device Manufacturers 2Health News:NuVasive to Present at ThinkEquity Partners 5th Annual Growth Conference 2Health News:NuVasive to Present at ThinkEquity Partners 5th Annual Growth Conference 3Health News:China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line 2Health News:China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line 3Health News:China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line 4Health News:Prostate Cancer Awareness Week to Screen Thousands 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: